5-Aminolevulinic Acid False-Positive Rates in Newly Diagnosed and Recurrent Glioblastoma: Do Pseudoprogression and Radionecrosis Play a Role? A Meta-Analysis

5-Aminolevulinic Acid False-Positive Rates in Newly Diagnosed and Recurrent Glioblastoma: Do Pseudoprogression and Radionecrosis Play a Role? A Meta-Analysis

BackgroundSeveral studies have confirmed the impact of 5-aminolevulinic acid (5-ALA) on the extent of resection in newly diagnosed glioblastoma (GBM). However, there are controversies on the 5-ALA fluorescence status in recurrent GBM surgery, with specific reference to pseudoprogression or radionecr...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Luca Ricciardi, Carmelo Lucio Sturiale, Alba Scerrati, Vito Stifano, Teresa Somma, Tamara Ius, Sokol Trungu, Michele Acqui, Antonino Raco, Massimo Miscusi, Giuseppe Maria Della Pepa
Natura:	Articolo
Lingua:	English
Pubblicazione:	Frontiers Media S.A. 2022-02-01
Serie:	Frontiers in Oncology
Soggetti:	glioblastoma high-grade glioma (HGG) recurrent glioblastoma 5-ALA fluorescence pseudoprogression radionecrosis
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2022.848036/full

Documenti analoghi

The influence of endothelial hyperplasia on pseudoprogression development in patients with glioblastoma
di: Petrović Marko, et al.
Pubblicazione: (2019-01-01)

The Potential Use of Radiomics with Pre-Radiation Therapy MR Imaging in Predicting Risk of Pseudoprogression in Glioblastoma Patients
di: Michael Baine, et al.
Pubblicazione: (2021-01-01)

The complementary role of MRI and FET PET in high-grade gliomas to differentiate recurrence from radionecrosis
di: Arpita Sahu, et al.
Pubblicazione: (2023-04-01)

Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME)
di: Archya Dasgupta, et al.
Pubblicazione: (2025-03-01)

Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review
di: Ingrid Sidibe, et al.
Pubblicazione: (2022-01-01)

In silico study of pseudoprogression in glioblastoma: collaboration of radiologists and radiation oncologists in the estimation of extent of high dose RT region
di: Renata Belanova, et al.
Pubblicazione: (2020-09-01)

Differentiating tumour progression from pseudoprogression in glioblastoma patients: a monoexponential, biexponential, and stretched-exponential model-based DWI study
di: Dan Liao, et al.
Pubblicazione: (2023-09-01)

Myeloid cells as potential targets for immunotherapy in pediatric gliomas
di: Stephen C. Frederico, et al.
Pubblicazione: (2024-03-01)

Editorial: Surgical approaches for the treatment of glioma
di: G. La Rocca, et al.
Pubblicazione: (2022-11-01)

Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas
di: Laiz Laura de Godoy, et al.
Pubblicazione: (2023-04-01)

Anti-PD-1 Vasculitis of the central nervous system or radionecrosis?
di: Roger Sun, et al.
Pubblicazione: (2017-12-01)

Histopathologically confirmed radiation-induced damage of the brain – an in-depth analysis of radiation parameters and spatio-temporal occurrence
di: Mario R. P. Kossmann, et al.
Pubblicazione: (2023-12-01)

Stereotactic radiotherapy for brain metastases: predictive factors of radionecrosis
di: Benoît Calderon, et al.
Pubblicazione: (2023-07-01)

Next-Generation Sequencing Comparative Analysis of DNA Mutations between Blood-Derived Extracellular Vesicles and Matched Cancer Tissue in Patients with Grade 4 Glioblastoma
di: Paolo Rosa, et al.
Pubblicazione: (2022-10-01)

Treatment of Laryngeal Radionecrosis with Hyperbaric Oxygen Therapy: A Case Report
di: Ying-Che Hsu, et al.
Pubblicazione: (2005-02-01)

Pseudoprogression; discussion of the concept of pseudoprogression on the characteristics of tomographic changes in liver metastases of colorectal cancer patients receiving bevacizumab therapy
di: Pinar Ozdemir Akdur, et al.
Pubblicazione: (2023-09-01)

Pseudoprogression and hyperprogression secondary to immunotherapy in lung cancer
di: R. Riera-Sala, et al.
Pubblicazione: (2023-09-01)

Radionecrosis cerebral en un adulto
di: Duniel Abreu Casas, et al.
Pubblicazione: (2024-02-01)

Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps
di: Valeria Cuccarini, et al.
Pubblicazione: (2024-04-01)

MR-Guided Radiotherapy for Brain and Spine Tumors
di: Danilo Maziero, et al.
Pubblicazione: (2021-03-01)

Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: A case report and review of the literature
di: Jacopo Lolli, et al.
Pubblicazione: (2023-03-01)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
di: Nozomi Hayakawa, et al.
Pubblicazione: (2023-01-01)

Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature
di: Jacopo Lolli, et al.
Pubblicazione: (2023-09-01)

Metabolic pitfall of pseudoprogression after epcoritamab treatment
di: Osamu Imataki, et al.
Pubblicazione: (2024-12-01)

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
di: Amrit S. Gonugunta, et al.
Pubblicazione: (2022-07-01)

Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure
di: Justin Leu, et al.
Pubblicazione: (2023-03-01)

Enlarged piloid astrocytoma of the midbrain: recurrence or pseudoprogression? A clinical case
di: Yu. Yu. Trunin, et al.
Pubblicazione: (2016-03-01)

Corrigendum: Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure
di: Justin Leu, et al.
Pubblicazione: (2023-04-01)

Pseudoprogression in patients on immunotherapy
di: D. I. Yudin, et al.
Pubblicazione: (2019-06-01)

Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
di: Zhu W, et al.
Pubblicazione: (2023-09-01)

Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma
di: Julianna K. Bronk, et al.
Pubblicazione: (2018-02-01)

Advances in Pseudoprogression of Immune Checkpoint Inhibitors  in Non-small Cell Lung Cancer
di: Yajun TONG, et al.
Pubblicazione: (2024-04-01)

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
di: Yongbo Xiang, et al.
Pubblicazione: (2023-07-01)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
di: Takumi Kageyama, et al.
Pubblicazione: (2022-11-01)

Impact of PTV margin reduction (2 mm to 0 mm) on pseudoprogression in stereotactic radiotherapy of solitary brain metastases
di: Justine Badloe, et al.
Pubblicazione: (2021-03-01)

Progress of fMRI on the recurrence and pseudoprogression in glioblastoma
di: FENG Quan⁃zhi, et al.
Pubblicazione: (2022-04-01)

Effects of Photons Irradiation on 18F-FET and 18F-DOPA Uptake by T98G Glioblastoma Cells
di: Francesca Pasi, et al.
Pubblicazione: (2020-11-01)

A study method using early dynamic acquisition of [18F]fluorodopa positron emission tomography for the differential diagnosis between progression and radionecrosis of brain metastases after radiotherapy
di: Ines Barrat, et al.
Pubblicazione: (2024-10-01)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
di: Eun Young Kim, et al.
Pubblicazione: (2019-04-01)

Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy
di: Vrankar Martina, et al.
Pubblicazione: (2018-10-01)